Brazil
Canada
Germany
Japan
Featured Content
Latest Press Releases
- May 24, 2022 Horizon Therapeutics plc to Present MIRROR Randomized Controlled Trial Primary Endpoint Data at The EULAR 2022 European Congress of Rheumatology
- May 17, 2022 Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab (HZN-7734) for the Treatment of Alopecia Areata
- May 16, 2022 Horizon Therapeutics plc Ranked Second in Overall Corporate Reputation in U.S. PatientView Survey of Patient Groups
Statements
Named Patient Use Programs
Featured Videos
Corporate Brochure
Corporate Brochure
Fact Sheets & Downloads
Logo Download
Horizon Logo | Full Color
Horizon Logo | Full Color, White Text
Horizon Logo | White
Horizon Logo | Charcoal
If you are looking for additional Horizon media assets, please contact corpcomms@horizontherapeutics.com.
Media Inquiries
For U.S. media inquiries, contact:
Geoff Curtis
Executive Vice President, Corporate Affairs & Chief Communications Officer
media@horizontherapeutics.com
+1 (888) 506-2562
For EU media inquiries, contact:
Ray Gordon
Managing Director
ray@gordonmrm.ie
+353 (87) 2417373